Skip to main content
OpenTrials
Completed

NCT Number: NCT01706588

Injectable Diclofenac for the Prevention of Post-operative Dental Pain

This is a prospective, randomised, double-blind, placebo-controlled, parallel group study in approximately 75 patients undergoing surgical removal of an impacted lower third molar.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

The School of Dentistry University of Birmingham

Birmingham, B4 6NN, United Kingdom

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Out-patients of either gender.
  • Patients aged ≥ 18 to ≤ 65 years old.
  • Subjects able and willing to give their written consent prior to inclusion in the study.
  • Female subjects of childbearing potential must (1) have a negative urine pregnancy test at the inclusion visit, (2) be using an appropriate method of contraception according to the definition of Note of ICH M3 Guideline (implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner), and (3) be willing to continue using the contraceptive method throughout the entire study period.
  • Subjects must (1) be able to comprehend the full nature and purpose of the study, including possible risks and side effects, (2) fully co-operate with the Investigator, (3) comply with the requirements of the entire study.
  • Patients undergoing surgical extraction of a single, fully or partially impacted mandibular 3rd molar requiring bone removal.

Exclusion criteria

General

  • Patients refusing to give written informed consent.
  • Patients not able to understand the purposes of the study or not willing to return for the control visits.
  • Patients with major psychiatric disorders that, in the investigator's opinion, could compromise study participation.
  • Patients enrolled in any clinical trial in the previous 3 months.
  • Employees of the study centre with direct involvement in the proposed study or other studies under the direction of the main investigator or study centre, as well as family members of the employees or investigator.
  • Pregnant or breast-feeding women.
  • Alcohol or drug abuse in the previous 12 months.
  • Clinically significant or unstable concomitant disease whose sequelae might interfere with the study evaluation parameters.

Treatment and study plan

Diclofenac Sodium

Drug

One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.

Other names: Diclofenac HPBCD

Primary outcomes

  1. Area Under the Curve (AUC) of the Pain Scores.

    Time frame: Pain scores will be measured over the time from end of surgery (time 0) to the 6 hour post-surgery

    Pain will be scored by the patient at the end of surgery (time 0) and at 15-minute intervals after surgery for a total of 6 hours on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).

Secondary outcomes

  1. Postsurgical Extra-oral Swelling

    Time frame: measured at 6 hours postsurgery, at day 3 and 1 week postsurgery

  2. Trismus

    Time frame: measured at 6 hours postsurgery, at day 3 and 1 week postsurgery

  3. Peak Pain Intensity

    Time frame: measured from end of surgery up to 12 hours postsurgery

  4. Time to First Use of Rescue Medication.

    Time frame: measured from end of surgery up to 1 week postsurgery

  5. Amount of Rescue Medication

    Time frame: consumed by the patient every 15-minutes postsurgery up to 6 hours postsurgery

  6. Rescue Medication Consumption

    Time frame: consumed by the patient from end of surgery up to 24 and up to 48 hours postsurgery

  7. Patient and Investigator Global Evaluation of the Effectiveness of Treatment

    Time frame: at 6 hour postsurgery and on Day 3

  8. Time to Onset of Pain

    Time frame: measured from end of surgery up to 12 hours postsurgery

  9. Wound Healing

    Time frame: at 6 hour postsurgery, and on day 3 and 1 week postsurgery

  10. Recurrent Bleeding

    Time frame: every hour up to 6 hour postsurgery

  11. Vital Signs

    Time frame: presurgery (within 30 days from surgery), at day of surgery (day 1), day 3 and 1 week postsurgery.

  12. Number of Patients With Adverse Events

    Time frame: from signature of the informed consent to 1 week postsurgery

Sponsors and collaborators

Lead sponsor

IBSA Institut Biochimique SA

Industry

Registry information

Official study title

Preliminary Evaluation of the Efficacy and Local Tolerability of Injectable Diclofenac at 5, 12.5, 25 and 50 mg/mL, Administered Locally Prior to Surgery for the Prevention of Post-operative Pain After Third Molar Surgery

Acronym: DP4

Important dates

Study start
2013
Primary completion
2013
Study completion
2013
First posted
Oct 15, 2012
Registry last updated
Sep 5, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.